Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week High on Better-Than-Expected Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares hit a new 52-week high during trading on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $84.49 and last traded at $83.8980, with a volume of 28401 shares trading hands. The stock had previously closed at $83.59.

The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 232.11%. The company had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. During the same quarter in the prior year, the company earned $1.54 earnings per share. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Record Q2 results beat expectations: Halozyme reported adjusted earnings of $2.28 per share, above the roughly $1.79-$1.82 consensus, while revenue rose 48% year over year to $481 million versus estimates near $402 million. Royalty revenue increased 50% to $308 million. Halozyme reports record second quarter 2026 results
• Positive Sentiment: 2026 guidance was raised: Management now expects revenue of $1.835 billion-$1.910 billion, royalty revenue of $1.220 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS range is above the approximately $8.02 analyst consensus. Halozyme Q2 earnings beat estimates
• Positive Sentiment: Commercial momentum expanded: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s royalty-driven platform model and broaden future revenue opportunities.
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO to “outperform” with a $110 price target. HC Wainwright raised its target to $115 and retained a “buy” rating, while TD Cowen increased its target to $105 and also rated the stock “buy.”
• Neutral Sentiment: Analyst views remain mixed at the elevated valuation: Citizens JMP raised its target to $93 with a “market outperform” rating, and Wells Fargo lifted its target to $95 while maintaining “equal weight.” Both targets remain below the recent trading level, suggesting some analysts see limited near-term upside.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on HALO shares. HC Wainwright increased their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a report on Friday. UBS Group restated a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday. Finally, Wall Street Zen raised Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $91.20.

Insider Activity at Halozyme Therapeutics

In other news, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total transaction of $124,653.75. Following the completion of the transaction, the director directly owned 42,044 shares in the company, valued at $3,225,195.24. This represents a 3.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $67.58, for a total value of $1,351,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $51,886,572.40. The trade was a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 72,477 shares of company stock valued at $5,102,643. Corporate insiders own 2.50% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership grew its stake in Halozyme Therapeutics by 29.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock valued at $241,337,000 after purchasing an additional 749,484 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after purchasing an additional 25,731 shares in the last quarter. Norges Bank bought a new stake in shares of Halozyme Therapeutics during the 4th quarter worth approximately $128,201,000. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $124,031,000. Finally, Federated Hermes Inc. boosted its holdings in shares of Halozyme Therapeutics by 8.5% in the 4th quarter. Federated Hermes Inc. now owns 1,574,621 shares of the biopharmaceutical company’s stock valued at $105,972,000 after buying an additional 123,917 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 20.2%

The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. The firm’s 50 day moving average is $76.48 and its two-hundred day moving average is $71.47. The firm has a market capitalization of $12.23 billion, a P/E ratio of 30.78, a PEG ratio of 0.36 and a beta of 0.85.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.